Hypoglycemia News and Research

RSS

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).

23 Apr 2010

Artificial pancreas system succeeds in maintaining near-normal glucose levels

An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients. The system, combining a blood glucose monitor and insulin pump technology with software that directs administration of insulin and the blood-sugar-raising hormone glucagon, was developed at Boston University.

15 Apr 2010

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

JumpStart Ventures invests $250,000 in Thermalin Diabetes

JumpStart Ventures, which invests in and partners with innovative, early-stage companies in Northeast Ohio, announced an investment commitment of $250,000 in Thermalin Diabetes Incorporated. The young biopharmaceutical company is developing new insulin treatments for patients with diabetes.

29 Mar 2010

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

CPEX Pharmaceuticals Inc. today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company’s nasal insulin product, Nasulin™. The study was designed to evaluate the efficacy and safety of Nasulin versus placebo over a 6-week treatment period in subjects with Type 2 diabetes who were being treated with basal insulin and oral anti-diabetes agents.

18 Mar 2010

ONGLYZA-metformin combination: FDA accepts NDA for review

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults.

17 Mar 2010

FDA approves Medtronic's MiniMed Paradigm integrated diabetes management system

Medtronic, Inc. today announced it has received U.S. Food and Drug Administration (FDA) approval for the MiniMed Paradigm® REAL-Time Revel™ System, the next generation of the industry’s only integrated diabetes management system (insulin pump therapy, continuous glucose monitoring (CGM) and diabetes therapy management software).

17 Mar 2010

Study: Hypoglycemia patients have mortality rate of 36.6%

In a study published in the March issue of Mayo Clinic Proceedings, researchers report that they have found a link between mild to moderate hypoglycemia (low blood sugar) and mortality in critically ill patients.

16 Mar 2010

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

15 Mar 2010

NDA for BYDUREON: FDA issues complete response letter

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for BYDUREON™ (exenatide for extended-release injectable suspension).

15 Mar 2010

Study explores incidence of eating disorders among type 1 diabetic patients

Diabetics, under the gun to better manage their disease by controlling their food intake and weight, may find themselves in the sticky wicket of needing treatment that makes them hungry, researchers said.

12 Mar 2010

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the “Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus” trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

10 Mar 2010

Novo Nordisk awarded contract by VA as primary source provider of insulin

Novo Nordisk, a global healthcare company and leader in diabetes care, announced it has been awarded a contract by the U.S. Department of Veterans Affairs as the primary source provider of insulin. The one year contract began on March 1, 2010 and the VA has the option to renew the contract annually for up to an additional four years.

From Novo Nordisk 3 Mar 2010

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration did not approve the additional indication for Bystolic® (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company’s Supplemental New Drug Application (sNDA).

23 Feb 2010

Marcadia Biotech commences Phase 1 clinical trial of MAR701 for type 2 diabetes

Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.

17 Feb 2010

Artificial pancreas can help manage diabetes in kids overnight

In a landmark study in children and teenagers with type 1 diabetes, JDRF-funded researchers at the University of Cambridge showed that using a first-generation artificial pancreas system overnight can lower the risk of low blood sugar emergencies while sleeping, and at the same time improve diabetes control.

6 Feb 2010

Tubing-Free Insulin Pump System improves glycemic control in diabetic patients

Albany College of Pharmacy and Health Sciences and The Endocrine Group researchers have concluded that the OmniPod® Insulin Management System significantly improved blood glucose control in diabetes patients who previously received insulin through multiple daily injections. The retrospective study results were published in the latest issue of Infusystems USA, in a study titled, 'Clinical Experience with a Tubing-Free Insulin Pump System.'

2 Feb 2010

MCADD screening is expensive but offers immense health benefits

Newborn screening for a metabolic disorder could lead to false positives -- adding stress to parents, costing money and possibly subjecting a baby to unnecessary follow-up treatment and dietary restrictions.

2 Feb 2010

Diabetes journal reviews the role of hypoglycemia in criminal behavior

Professor Vincent Marks, a leading authority on the forensic aspects of hypoglycemia and its role in criminal behavior, discusses how hypoglycemia-related neuroglycopenia can cause behavioral changes, which can bring people with diabetes into conflict with the law. "

31 Jan 2010

Treating septic shock patients with intensive insulin therapy does not reduce risk of in-hospital death

Treating adults with septic shock with intensive insulin therapy to counter elevated blood glucose levels associated with corticosteroid therapy did not result in a reduced risk of in-hospital death, compared to patients who received conventional insulin therapy, according to a study in the January 27 issue of JAMA.

27 Jan 2010